Maeda Toshihisa, Miura Yasushi, Fukuda Koji, Hayashi Shinya, Kurosaka Masahiro
Department of Orthopaedic Surgery, Kobe University Graduate School of Medicine, Chuo, Kobe, Hyogo 650‑0017, Japan.
Mol Med Rep. 2015 Oct;12(4):5191-6. doi: 10.3892/mmr.2015.4097. Epub 2015 Jul 20.
Decoy receptor 3 (DcR3) is expressed in rheumatoid arthritis fibroblast‑like synoviocytes (RA‑FLS) and downregulates the expression of tryptophan hydroxylase 1 (TPH1), which is the rate‑limiting enzyme in serotonin synthesis. The aim of the present study was to determine the specificity of the effects of DcR3 on TPH1 in RA‑FLS, and therefore determine whether DcR3 had the potential to modulate the pathogenesis of RA. The present study also aimed to compare the effects of DcR3 and inflammatory cytokines on the expression of TPH1 in RA‑FLS and osteoarthritis (OA)‑FLS. Primary cultured RA‑ or OA‑FLS were incubated with 1.0 µg/ml DcR3‑Fc protein or 1.0 µg/ml control immunoglobulin G (IgG)1 for 12 h, or with 1.0 ng/ml tumor necrosis factor (TNF)α, 1.0 ng/ml interleukin (IL)‑1β or serum‑free Opti‑MEM only, for 24 h. The relative mRNA expression levels of TPH1 were subsequently quantified using reverse transcription‑polymerase chain reaction. The expression of serotonin in RA or OA synovial tissue was detected using immunohistochemistry. The mRNA expression of TPH1 was observed in both RA‑ and OA‑FLS and was significantly decreased following treatment with DcR3 in the RA‑FLS, however, not in the OA‑FLS. The mRNA expression of TPH1 was significantly decreased following treatment with TNFα or IL‑1β in both the RA‑ and OA‑FLS. The expression of serotonin in the multi‑layered lining synovial cells of RA and the outer layer lining synovial cells of OA was detected using immunohistochemistry. The present study is the first, to the best of our knowledge, to demonstrate that the expression of TPH1 in FLS is downregulated by inflammatory cytokines, and that DcR3 suppressed the expression of TPH1 in RA‑FLS in a disease‑specific manner. These results suggested that synovial serotonin may be involved in the pathogenesis of RA, and that TPH1 and DcR3 may be potential therapeutic targets for the treatment of RA.
诱饵受体3(DcR3)在类风湿关节炎成纤维样滑膜细胞(RA-FLS)中表达,并下调色氨酸羟化酶1(TPH1)的表达,TPH1是5-羟色胺合成中的限速酶。本研究的目的是确定DcR3对RA-FLS中TPH1作用的特异性,从而确定DcR3是否具有调节RA发病机制的潜力。本研究还旨在比较DcR3和炎性细胞因子对RA-FLS和骨关节炎(OA)-FLS中TPH1表达的影响。将原代培养的RA-FLS或OA-FLS与1.0μg/ml DcR3-Fc蛋白或1.0μg/ml对照免疫球蛋白G(IgG)1孵育12小时,或与1.0 ng/ml肿瘤坏死因子(TNF)α、1.0 ng/ml白细胞介素(IL)-1β或仅无血清的Opti-MEM孵育24小时。随后使用逆转录-聚合酶链反应定量TPH1的相对mRNA表达水平。使用免疫组织化学检测RA或OA滑膜组织中5-羟色胺的表达。在RA-FLS和OA-FLS中均观察到TPH1的mRNA表达,并且在RA-FLS中用DcR3处理后显著降低,然而在OA-FLS中未降低。在RA-FLS和OA-FLS中,用TNFα或IL-1β处理后,TPH1的mRNA表达均显著降低。使用免疫组织化学检测RA多层衬里滑膜细胞和OA外层衬里滑膜细胞中5-羟色胺的表达。据我们所知,本研究首次证明炎性细胞因子可下调FLS中TPH1的表达,并且DcR3以疾病特异性方式抑制RA-FLS中TPH1的表达。这些结果表明滑膜5-羟色胺可能参与RA的发病机制,并且TPH1和DcR3可能是治疗RA的潜在治疗靶点。